◀ Back to IL5

IL5 — JAK2

Pathways - manually collected, often from reviews:

• NCI Pathway Database IL5-mediated signaling events: IL5/IL5RA/CSF2RB (hexamer)/JAK2/JAK2 complex (CSF2RB-IL5-IL5RA-JAK2) → STAT5 (STAT5A/STAT5B) (modification, activates) Mui et al., EMBO J 1995, Kouro et al., Int Immunol 1996
  Evidence: assay
• NCI Pathway Database IL5-mediated signaling events: IL5/IL5RA/CSF2RB (hexamer)/JAK2/JAK2 complex (CSF2RB-IL5-IL5RA-JAK2) → STAT5-active (STAT5A/STAT5B) (modification, activates)
  Mui et al., EMBO J 1995, Kouro et al., Int Immunol 1996
  Evidence: assay
• NCI Pathway Database IL5-mediated signaling events: GRB2 (GRB2) → IL5/IL5RA/CSF2RB (hexamer)/JAK2/JAK2/SHP2 complex (CSF2RB-IL5-IL5RA-JAK2-PTPN11) (modification, collaborate)
  Pazdrak et al., J Exp Med 1997
  Evidence: physical interaction
• NCI Pathway Database IL5-mediated signaling events: GRB2 (GRB2) → IL5/IL5RA/CSF2RB (hexamer)/JAK2/JAK2/SHP2/GRB2 complex (CSF2RB-IL5-IL5RA-JAK2-PTPN11-GRB2) (modification, collaborate)
  Pazdrak et al., J Exp Med 1997
  Evidence: physical interaction
• NCI Pathway Database IL5-mediated signaling events: IL5/IL5RA/CSF2RB (hexamer)/JAK2/JAK2/SHP2 complex (CSF2RB-IL5-IL5RA-JAK2-PTPN11) → IL5/IL5RA/CSF2RB (hexamer)/JAK2/JAK2/SHP2/GRB2 complex (CSF2RB-IL5-IL5RA-JAK2-PTPN11-GRB2) (modification, collaborate)
  Pazdrak et al., J Exp Med 1997
  Evidence: physical interaction
• NCI Pathway Database IL5-mediated signaling events: IL5 (IL5) → IL5/IL5RA/JAK2 complex (IL5RA-JAK2-IL5) (modification, collaborate)
  Czabotar et al., Cytokine 2000*, Tavernier et al., Proc Natl Acad Sci U S A 1992, Murata et al., J Exp Med 1992*, Tavernier et al., Cell 1991, Devos et al., EMBO J 1991, Johanson et al., J Biol Chem 1995, Milburn et al., Nature 1993*, Takaki et al., J Exp Med 1993*, Li et al., Proc Natl Acad Sci U S A 1997*, Ogata et al., Blood 1998
  Evidence: mutant phenotype, assay, physical interaction
• NCI Pathway Database IL5-mediated signaling events: IL5 (IL5) → IL5RA/JAK2 complex (IL5RA-JAK2) (modification, collaborate)
  Czabotar et al., Cytokine 2000*, Tavernier et al., Proc Natl Acad Sci U S A 1992, Murata et al., J Exp Med 1992*, Tavernier et al., Cell 1991, Devos et al., EMBO J 1991, Johanson et al., J Biol Chem 1995, Milburn et al., Nature 1993*, Takaki et al., J Exp Med 1993*, Li et al., Proc Natl Acad Sci U S A 1997*, Ogata et al., Blood 1998
  Evidence: mutant phenotype, assay, physical interaction
• NCI Pathway Database IL5-mediated signaling events: IL5/IL5RA/JAK2 complex (IL5RA-JAK2-IL5) → IL5RA/JAK2 complex (IL5RA-JAK2) (modification, collaborate)
  Czabotar et al., Cytokine 2000*, Tavernier et al., Proc Natl Acad Sci U S A 1992, Murata et al., J Exp Med 1992*, Tavernier et al., Cell 1991, Devos et al., EMBO J 1991, Johanson et al., J Biol Chem 1995, Milburn et al., Nature 1993*, Takaki et al., J Exp Med 1993*, Li et al., Proc Natl Acad Sci U S A 1997*, Ogata et al., Blood 1998
  Evidence: mutant phenotype, assay, physical interaction
• NCI Pathway Database IL5-mediated signaling events: IL5/IL5RA/CSF2RB (hexamer)/JAK2/JAK2 complex (CSF2RB-IL5-IL5RA-JAK2) → PI3K complex (PIK3CA-PIK3R1) (modification, activates)
  Dijkers et al., Oncogene 1999
  Evidence: mutant phenotype, assay
• NCI Pathway Database IL5-mediated signaling events: IL5/IL5RA/JAK2 complex (IL5RA-JAK2-IL5) → IL5/IL5RA/CSF2RB (hexamer)/JAK2/JAK2 complex (CSF2RB-IL5-IL5RA-JAK2) (modification, collaborate)
  Sun et al., Blood 1999, Mulhern et al., J Mol Biol 2000, Rossjohn et al., Blood 2000, Carr et al., Cell 2001, Carr et al., Acta crystallographica. Section F, Structural biology and crystallization communications 2006, Martinez-Moczygemba et al., J Leukoc Biol 2007*, Tavernier et al., Cell 1991, Lei et al., J Leukoc Biol 2008*, Sato et al., J Exp Med 1994, Cornelis et al., Eur J Immunol 1995*, Johanson et al., J Biol Chem 1995, Woodcock et al., EMBO J 1994, Kouro et al., Int Immunol 1996, Ogata et al., Blood 1998
  Evidence: mutant phenotype, assay, physical interaction
• NCI Pathway Database IL5-mediated signaling events: IL5/IL5RA/JAK2 complex (IL5RA-JAK2-IL5) → CSF2RB (dimer) complex (CSF2RB) (modification, collaborate)
  Sun et al., Blood 1999, Mulhern et al., J Mol Biol 2000, Rossjohn et al., Blood 2000, Carr et al., Cell 2001, Carr et al., Acta crystallographica. Section F, Structural biology and crystallization communications 2006, Martinez-Moczygemba et al., J Leukoc Biol 2007*, Tavernier et al., Cell 1991, Lei et al., J Leukoc Biol 2008*, Sato et al., J Exp Med 1994, Cornelis et al., Eur J Immunol 1995*, Johanson et al., J Biol Chem 1995, Woodcock et al., EMBO J 1994, Kouro et al., Int Immunol 1996, Ogata et al., Blood 1998
  Evidence: mutant phenotype, assay, physical interaction
• NCI Pathway Database IL5-mediated signaling events: IL5/IL5RA/CSF2RB (hexamer)/JAK2/JAK2 complex (CSF2RB-IL5-IL5RA-JAK2) → CSF2RB (dimer) complex (CSF2RB) (modification, collaborate)
  Sun et al., Blood 1999, Mulhern et al., J Mol Biol 2000, Rossjohn et al., Blood 2000, Carr et al., Cell 2001, Carr et al., Acta crystallographica. Section F, Structural biology and crystallization communications 2006, Martinez-Moczygemba et al., J Leukoc Biol 2007*, Tavernier et al., Cell 1991, Lei et al., J Leukoc Biol 2008*, Sato et al., J Exp Med 1994, Cornelis et al., Eur J Immunol 1995*, Johanson et al., J Biol Chem 1995, Woodcock et al., EMBO J 1994, Kouro et al., Int Immunol 1996, Ogata et al., Blood 1998
  Evidence: mutant phenotype, assay, physical interaction
• NCI Pathway Database IL5-mediated signaling events: IL5/IL5RA/CSF2RB (hexamer)/JAK2/JAK2 complex (CSF2RB-IL5-IL5RA-JAK2) → SHP2 (PTPN11) (modification, collaborate) Pazdrak et al., J Exp Med 1997
  Evidence: mutant phenotype, assay, physical interaction
• NCI Pathway Database IL5-mediated signaling events: IL5/IL5RA/CSF2RB (hexamer)/JAK2/JAK2 complex (CSF2RB-IL5-IL5RA-JAK2) → IL5/IL5RA/CSF2RB (hexamer)/JAK2/JAK2/SHP2 complex (CSF2RB-IL5-IL5RA-JAK2-PTPN11) (modification, collaborate)
  Pazdrak et al., J Exp Med 1997
  Evidence: mutant phenotype, assay, physical interaction
• NCI Pathway Database IL5-mediated signaling events: SHP2 (PTPN11) → IL5/IL5RA/CSF2RB (hexamer)/JAK2/JAK2/SHP2 complex (CSF2RB-IL5-IL5RA-JAK2-PTPN11) (modification, collaborate)
  Pazdrak et al., J Exp Med 1997
  Evidence: mutant phenotype, assay, physical interaction
• Reactome Reaction: IL5 → JAK2 (indirect_complex) Tavernier et al., Cell 1991, Devos et al., EMBO J 1991
• Reactome Reaction: IL5 → JAK2 (reaction) Sakamaki et al., EMBO J 1992, Duronio et al., J Biol Chem 1992, Tavernier et al., Cell 1991, Devos et al., EMBO J 1991, Sorensen et al., J Biol Chem 1989, Quelle et al., Mol Cell Biol 1994, Feng et al., Mol Cell Biol 1997, Bone et al., J Biol Chem 1997, Flores-Morales et al., Mol Cell Endocrinol 1998

Text-mined interactions from Literome

Zahn et al., Cytokine 2000 : IL-5 Induced JAB-JAK2 interaction ... Without JAB, stimulation with wild-type and re-engineered single chain ( sc ) IL-5 induced a time dependent phosphorylation of JAK2
Miura et al., J Immunol 2001 (MAP Kinase Signaling System) : However, only IL-3 and IL-5 induced Janus kinase 2 and STAT5 phosphorylation
Morokata et al., Int Immunopharmacol 2002 : Furthermore, YM-90709 inhibited the IL-5 induced but not GM-CSF induced tyrosine phosphorylation of Janus kinase 2 (JAK2) in eosinophilic HL-60 clone 15 cells
To et al., Br J Cancer 2004 (Cell Transformation, Neoplastic...) : The interleukin mediated Janus kinase ( JAK ) /STAT pathway plays a crucial role in carcinogenesis
Munitz et al., Blood 2006 (Calcium Signaling...) : Cross linking of IRp60 inhibited IL-5 mediated JAK2 phosphorylation as well as eotaxin- and IL-5/GM-CSF mediated ERK1/2 and p38 phosphorylation
Takatsu et al., Adv Immunol 2009 (Hypersensitivity) : JAK2 and JAK1 tyrosine kinase are constitutively associated with IL-5Ralpha and betac, respectively, and are activated by IL-5 stimulation
Li et al., PloS one 2012 (Hypereosinophilic Syndrome) : The F/P can enhance the IL-5 induced JAK2 activation, and further results indicated that JAK2 inhibition blocked IL-5 induced cellular migration and activation of the EOL-1 and PC cells in vitro
Caldenhoven et al., J Biol Chem 1995 (Acute-Phase Reaction) : Recent reports have shown that IL-5 induces tyrosine phosphorylation of JAK2 followed by the subsequent cell type-specific activation of either STAT1 alpha or STAT5
Alam et al., Int Arch Allergy Immunol 1995 : The interleukin-5/receptor interaction activates Lyn and Jak2 tyrosine kinases and propagates signals via the Ras-Raf-1-MAP kinase and the Jak-STAT pathways in eosinophils
van der Bruggen et al., Blood 1995 : IL-5 induced rapid and transient tyrosine phosphorylation of JAK2
Kouro et al., Int Immunol 1996 : In the studies described here, we demonstrate that IL-5 , IL-3 or GM-CSF stimulation induces the tyrosine phosphorylation of JAK2 , and to a lesser extent JAK1, and of STAT5
de Groot et al., J Biol Chem 1997 : By contrast, IL-5 induced activation of the tyrosine kinase Janus kinase 2 seems to be a prerequisite for TRE- and DSE dependent transcription
Paul et al., Am J Hematol 1997 (Leukemia, Myeloid) : We found that phosphorylation of beta c and JAK2 in response to GM-CSF and IL-5 could be markedly enhanced by depriving cells of endogenous GM-CSF
Ogata et al., Blood 1998 : IL-5 stimulation resulted in tyrosine phosphorylation of JAK2, JAK1 , betac, and STAT5
Adachi et al., Am J Physiol 1998 : IL-5 activates Lyn, Syk, and JAK2 and propagates signals through the Ras-MAPK and JAK-STAT pathways